The large shareholder in SLA who is utilising Solagran products including Reopren has increased order sizes, demand in New Zealand is strengthening as patients whose families have a history of alzheimers embrace the treatment. Few potential patients are ware of this treatment at this time.
Sales are at $3500 per course and increasing.
This information came from one of the purchasers.
DYOR
IMOO
The large shareholder in SLA who is utilising Solagran products...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
